TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04494828
Drug: Normal saline group
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
Study: NCT01103440
Drug: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
Study: NCT00114127
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg duloxetine 1x per day
Study: NCT00114127
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
Study: NCT03072043
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
Study: NCT00699413
Drug: nutrition education plus active supplement
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal.
Study: NCT00699413
Drug: nutrition education plus inactive supplement
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste.
Study: NCT02779777
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT01466205
Drug: DAR-0100A
Normalized name: DAR-0100A
DrugBank: DAR-0100A (DB16139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
Study: NCT01943786
Drug: FOLFIRI + Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
Study: NCT04571060
Drug: Zavegepant
Normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of zavegepant
Study: NCT02186483
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin,1000mg, once daily
Study: NCT01736033
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet(0.2mg) orally q.d.
Study: NCT01736033
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet(5mg) orally q.d.
Study: NCT03328832
Drug: Topical tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
Study: NCT03328832
Drug: rivaroxaban (10mg)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
Study: NCT00049257
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered Day 1 of each cycle. AUC=6.
Study: NCT00049257
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered Days 1, 8, and 15 of each cycle. 100mg/m2
Study: NCT00439101
Drug: Megstrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
Study: NCT02559973
Drug: RBP-6000
Normalized name: COCAINE ESTERASE (RBP-8000)
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
Study: NCT02559973
Drug: SUBOXONE Sublingual Film
Normalized name: buprenorphine / naloxone Sublingual Film [Suboxone]
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
Study: NCT02799589
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
Study: NCT02799589
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
Study: NCT00841087
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
Study: NCT00841087
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Injection subcutaneously at bedtime
Study: NCT00841087
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection subcutaneously immediately before each meal.
Study: NCT01060254
Drug: JNJ-42160443
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
Study: NCT01949129
Drug: VP16
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
Study: NCT01949129
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2x5 mg/kg BW, 1 day
Study: NCT01949129
Drug: Treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 14g/m² BS, 3 days
Study: NCT01949129
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m² BS, 5 days
Study: NCT01949129
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iV, dosage according therapeutic drug monitoring, 4 days
Study: NCT01949129
Drug: ATG Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Study: NCT00374517
Drug: Pimonidazole hydrochloride
Normalized name: Pimonidazole
DrugBank: Pimonidazole (DB12485)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01079364
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
Study: NCT01079364
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
Study: NCT01079364
Drug: Premixed insulin (Insulin Aspart 30/70 )
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
Study: NCT01514721
Drug: Travoprost/Timolol Maleate BAK-Free Fixed Combination
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
Study: NCT00132301
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy agent
Study: NCT00132301
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: steroid in combination with chemotherapy agent
Study: NCT04096105
Drug: CC-93538
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose CC-93538 SC
Study: NCT03345303
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib Injectable Solution
Study: NCT02012218
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02691026
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01371058
Drug: high maintenance clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
Study: NCT01371058
Drug: routine dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
Study: NCT03186625
Drug: Compound Panax Notoginseng Granule
Normalized name: Panax notoginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months.
Study: NCT01796288
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02623205
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Study: NCT02269696
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative metoprolol infusion.
Study: NCT00833027
Drug: sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg/day - tablet for 24 weeks
Study: NCT00169221
Drug: Iressa (Gefitinib)
Normalized name: Iressa
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: postoperative chemoradiotherapy with cisplatin + gefitinib
Study: NCT02116842
Drug: 0.1% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural block in early labour.
Study: NCT02116842
Drug: 0.075% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural block in early labour.
Study: NCT00322842
Drug: G-CSF Plus Plerixafor
Normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study: NCT01890265
Drug: Pamrevlumab
Normalized name: Pamrevlumab
DrugBank: Pamrevlumab (DB14952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT01890265
Drug: Sub-Study: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone concomitant therapy will not be provided by the Sponsor.
Study: NCT01890265
Drug: Sub-Study: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib concomitant therapy will not be provided by the Sponsor.
Study: NCT00360178
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00553410
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
Study: NCT00553410
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
Study: NCT00087087
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02725242
Drug: Budesonide/formoterol (160/4.5 μg/d)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
Study: NCT03360760
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Study: NCT02418663
Drug: Fluid challenge (250 ml Lactated Ringer's solution)
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above
Study: NCT03360760
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Study: NCT04248205
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
Study: NCT01928628
Drug: Lercanidipine 10mg
Normalized name: lercanidipine 10 MG
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01928628
Drug: Lercanidipine10mg /Valsartan 80mg
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01928628
Drug: Lercanidipine 10mg /Valsartan 160mg
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01928628
Drug: Lercanidipin 10mg Placebo
Normalized name: lercanidipine 10 MG
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01928628
Drug: Lercanidipine10mg /Valsartan 80mg Placebo
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02913157
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally administered Hydroxychloroquine
Study: NCT01541488
Drug: BI 1021958
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01541488
Drug: BI 1021958
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drinking solution / tablet
Study: NCT02772978
Drug: Tolcapone
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
Study: NCT02678299
Drug: PREBEN
Normalized name: AVOBENZONE 25.6 mg in 1 mL / HOMOSALATE 106.5 mg in 1 mL / OCTISALATE 42.6 mg in 1 mL / OCTOCRYLENE 23.43 mg in 1 mL / OXYBENZONE 51.12 mg in 1 mL TOPICAL SPRAY [Prebel Nude Protect SPF 70 Sunscreen]
DrugBank: Oxybenzone (DB01428)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02725242
Drug: Budesonide (400μg/d)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
Study: NCT02071888
Drug: CB-839 and low dose dexamethasone
Normalized name: BroveX CB
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CB-839 and low dose dexamethasone
Study: NCT02071888
Drug: CB-839, pomalidomide, and low dose dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CB-839, pomalidomide, and low dose dexamethasone
Study: NCT01531712
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 / / 40mg/m2
Study: NCT01531712
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/day
Study: NCT01531712
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/m2 (only in QT)
Study: NCT00101907
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
Study: NCT00101907
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
Study: NCT00101907
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
Study: NCT01997515
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
Study: NCT03647228
Drug: IONIS-ENaCRx
Normalized name: Ionis-enacrx
DrugBank: Cofirasersen (DB19037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
Study: NCT00434967
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 32 mg oral tablet
Study: NCT01207206
Drug: oral ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception
Study: NCT03464526
Drug: Orvepitant
Normalized name: Orvepitant
DrugBank: Orvepitant (DB12427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily, oral
Study: NCT02444572
Drug: Enoxaparin 4000 IU
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01107639
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5
Study: NCT00862446
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram/kg/day daily until on feeds
Study: NCT01107639
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5
Study: NCT01848756
Drug: SNX-5422
Normalized name: SNX-5422
DrugBank: SNX-5422 (DB06070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
Study: NCT00939913
Drug: intravenous NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)